cytodyn reports strong results from eind covid-19 patients treated with leronlimab ; none of patients have demonstrated remarkable recoveries
cytodyn reports strong results from eind covid-19 patients treated with leronlimab ; none of patients have demonstrated remarkable recoveries
bruce patterson, m.d., chief executive officer and founder of incelldx, a diagnostics company and an advisor to cytodyn, expanded on these findings by stating, we are excited that patients are responding extremely well to leronlimab as expected from the novel mechanism of covid-19 pathogenesis we discovered and will be reporting in the coming days. nader pourhassan, ph.d., president and chief executive officer of cytodyn said, we believe these results, although anecdotal, are very impressive and the number of patients treated under eind is rapidly increasing.", 


































"all patient blood samples were evaluated and important powerful results from the effect of leronlimab were demonstrated in almost all of these patients.")